AC
KYMR icon

AXQ Capital’s Kymera Therapeutics KYMR Stock Holding History

AXQ Capital’s Portfolio KYMR Stock Details KYMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q2 		– Sell
-7,478
Closed -$222K – 447
2023
Q1 		$222K Sell
7,478
-3,461
-32% -$112K 0.09% 385
2022
Q4 		$273K Buy
+10,939
New +$292K 0.19% 203

Other funds holding KYMR

AVLSA
Atlas Venture Life Science Advisors Cambridge, Massachusetts $881M AUM 160.77% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.49B AUM 208.7% 1-Year Est. Return

AXQ Capital's KYMR Position: Q2 2023 in Review

AXQ Capital sold out of Kymera Therapeutics (KYMR) in Q2 2023, closing a stake of 7,478 shares — an estimated $222K sold.

AXQ Capital first reported a position in KYMR in Q4 2022 and held it in 2 quarters. The position peaked at $273K in Q4 2022. 128 funds tracked by Wall St. Rank hold KYMR as of Q2 2023.

  • AXQ Capital reported no remaining Kymera Therapeutics position as of Q2 2023 after selling out during the quarter.
  • AXQ Capital sold 7,478 Kymera Therapeutics shares in Q2 2023, an estimated $222K.
  • AXQ Capital first reported a position in Kymera Therapeutics in Q4 2022 and held it in 2 quarters.
  • AXQ Capital's Kymera Therapeutics position peaked at $273K in Q4 2022.
  • 128 funds tracked by Wall St. Rank held Kymera Therapeutics as of Q2 2023.

Based on AXQ Capital's 13F filing for Q2 2023, filed 11 Aug 2023.